Deyaa Adib, MD, on Evaluating HER2 TAC T-Cell Therapy in Solid Tumors
The chief medical officer of Triumvira Immunologics discussed updates from the TACTIC-2 study presented at ESMO Congress 2022.
Jeffrey Miller, MD, on Engaging NK Cells in Solid Tumors
The deputy director of the Masonic Cancer Center discussed the preclinical findings of his study on a TriKE engager and NK cells.
David S. Hong, MD, on the SURPASS Clinical Trial and TCR T-cell Therapy in Solid Tumors
Hong presented data from the SURPASS clinical trial at the 2022 European Society for Medical Oncology (ESMO) Congress.
Weijia Fang, MD, and Guoqiang Ai, MD, on the Future of IMC001 in Gastric and Colorectal Cancer
Fang commented on a limitation of the clinical trial pointed out at the European Society for Medical Oncology (ESMO) 2022 Congress.
Weijia Fang, MD, and Tianhang Luo, MD, on EpCAM-Targeted CAR-T Therapy in Advanced Colorectal and Gastric Cancer
Fang recently presented at the European Society for Medical Oncology (ESMO) 2022 Congress.
Noopur Raje, MD, on bb21217 Data in R/R Multiple Myeloma
The director, Center for Multiple Myeloma, Massachusetts General Hospital, discussed data seen with bb21217 in R/R MM.
Adam D. Cohen, MD, on Cilta-Cel for Lenalidomide-Refractory Multiple Myeloma
The director of myeloma immunotherapy at University of Pennsylvania discussed cilta-cel's efficacy in lenalidomide-refractory multiple myeloma.
Mark Forman, MD, PhD, on Genetic Testing and Further Research in Frontotemporal Dementia
The chief medical officer of Passage Bio discussed research needs in FTD.
Developing a Safer Allogeneic Cell Therapy for Ovarian Cancer
Michael Heffernan, chairman and chief executive officer, Avenge Bio, discussed AVB-001's lower systemic toxicity profile seen in preclinical studies.
Alexis Thompson, MD, MPH, on the Impact of Beti-Cel's Approval in Beta Thalassemia
The primary investigator and chief of hematology at Children’s Hospital of Philadelphia discussed the collaboration and research that went into developing beti-cel.
Mark Forman, MD, PhD, on ICM Administration of Gene Therapy in Frontotemporal Dementia
The chief medical officer of Passage Bio discussed the phase 1/2 upliFT-D study of PBFT02.
Developing a More Precise Allogeneic Cell Therapy for Ovarian Cancer
Michael Heffernan, chairman and chief executive officer, Avenge Bio, discussed the IND clearance of AVB-001 and the soon-to-initiate phase 1 trial.
Irene Agodoa, MD, on Addressing GVHD Risks in Treating Hematologic Malignancies
The senior vice president and head of medical affairs at Orca Bio discussed how Orca-T has been developed to lower the risk of graft-versus-host disease.
Laurent Poirot, PhD, on the FDA’s IND Clearance for UCART20x22
The senior vice president of immunology at Cellectis discussed the company’s investigational dual-targeted CAR-T therapy for B-cell malignancies.
Alexis Thompson, MD, MPH, on Qualifying Treatment Centers for Beti-Cel in Thalassemia
The primary investigator and chief of hematology at Children’s Hospital of Philadelphia discussed requirements for administering beti-cel.
Irene Agodoa, MD, on Assessing Orca-T for Safer Cell Therapy in Hematologic Malignancies
The senior vice president and head of medical affairs at Orca Bio discussed the initiation of the Precision-T phase 3 trial.
Alexis Thompson, MD, MPH, on Beti-Cel's Approval in β-Thalassemia
The primary investigator and chief of hematology at Children’s Hospital of Philadelphia discussed beti-cel's approval.
Merit Cudkowicz, MD, on Evaluating Mesenchymal Cell Therapy for ALS
BrainStorm Cell Therapeutics has decided to submit a BLA for NurOwn in ALS following an erratum to a phase 3 trial.
Shannon L. Maude, MD, PhD, on Favorable Safety of Tisagenlecleucel in Pediatric B-ALL
The oncologist from Children's Hospital of Philadelphia discussed long-term safety data with tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia.
Monitoring and Support for Patients Receiving CAR T-Cell Therapy
Experts discuss providing supportive care to patients receiving CAR T-cell therapy.
Nilanjan Ghosh, MD, PhD, on Paving the Way for CAR T Therapies in Lymphomas
The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed work that needs to be done to support the use of CAR T therapy.
The Power of Partnership in CMT Gene Therapy Research
Susan Ruediger, founder and chief mission officer, CMT Research Foundation, discussed the origins of the CMTRF.
Richard Fessler, MD, on Progress With Cell Therapy in Spinal Cord Injury
The professor of neurosurgery at Rush University Medical School discussed the potential of Lineage Cell’s LCTOPC1 cell therapy.
Milan Zdravkovic, MD, PhD, on Using CRISPR-Cas Systems to Target Pathogens
Milan Zdravkovic, MD, PhD, chief medical officer of SNIPR Biome, discussed the company’s ongoing research on targeting E Coli in the blood with CRISPR-based medication.
Mazyar Shadman, MD, MPH, on Addressing Unmet Needs in Follicular Lymphoma With MB-106
The associate professor at Fred Hutch Cancer Center discussed next steps with the clinical trial being conducted Fred Hutch Cancer Center.
Nilanjan Ghosh, MD, PhD, on New Avenues of CAR T Research in Lymphoma
The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed new CAR T-cell therapies being investigated for hematologic malignancies.
Susan Ruediger on Partnering to Develop CMT Gene Therapies
Susan Ruediger, founder and chief mission officer, CMT Research Foundation, discussed a new partnership with Nationwide Children’s Hospital.
Steven W. Pipe, MD, on Conducting Further Research in Hemophilia
The director of the Pediatric Hemophilia and Coagulation Disorders Program at CS Mott Children’s Hospital discussed current studies evaluating gene therapies in hemophilia.
Peter Bross, MD, on the Importance of Transparency and Communication With the FDA
The chief of the oncology branch of the Center for Biologics Evaluation and Research at the FDA discussed how academia and industry can work best with regulatory agencies.
Paul Wuh-Liang Hwu, MD, PhD, on Questions Remaining With AADC Deficiency
Upstaza has been granted marketing authorization by the European Commission.
